valaciclovir/pharmathen international 500mg film-coated tablets tablets film-coated
pharmathen s.a. - valaciclovir (valaciclovir hydrochloride) - tablets film-coated - 500mg
atorvastatin pharmathen 40 milligram film coated tablet
pharmathen s.a. - atorvastatin - film coated tablet - 40 milligram - hmg coa reductase inhibitors
atorvastatin pharmathen 20 milligram film coated tablet
pharmathen s.a. - atorvastatin calcium - film coated tablet - 20 milligram - hmg coa reductase inhibitors
atorvastatin pharmathen 80 milligram film coated tablet
pharmathen s.a. - atorvastatin calcium - film coated tablet - 80 milligram - hmg coa reductase inhibitors
atorvastatin pharmathen 10 milligram film coated tablet
pharmathen s.a. - atorvastatin calcium - film coated tablet - 10 milligram - hmg coa reductase inhibitors
topiramate pharmathen 100 milligram film coated tablet
pharmathen s.a. - topiramate - film coated tablet - 100 milligram
topiramate pharmathen 25 milligram film coated tablet
pharmathen s.a. - topiramate - film coated tablet - 25 milligram
topiramate pharmathen 50 milligram film coated tablet
pharmathen s.a. - topiramate - film coated tablet - 50 milligram
topiramate pharmathen 200 milligram film coated tablet
pharmathen s.a. - topiramate - film coated tablet - 200 milligram
grepid
pharmathen s.a. - clopidogrel (as besilate) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.